This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Since 2019, pharmaceuticalcompanies have been speeding to integrate digital channels and processes into their marketing efforts and patient outreach, to prepare for the wave of digitisation in the healthcare industry. As part of these efforts, customer experience (CX) became a key focus area to ensure customer engagement and loyalty.
For example, a pharmaceuticalcompany could create a blog post about a new drug that it is developing. For example, a pharmaceuticalcompany could create a whitepaper about a particular medical condition.
By Yuri Fesko, MD | Our latest whitepaper, delves deep into the symbiotic relationship between diagnostic labs, pharmaceuticalcompanies, and healthcare providers in the era of precision medicine.
The pandemic has triggered a change in how pharmaceuticalcompanies are engaging with healthcare professionals. When IQVIA polled non COVID-19 treating Italian HCPs in March when the crisis was at its worst, it asked HCPs if they still welcomed pharmaceuticalcompany engagement during the crisis. The answer was yes.
The pharmaceutical industry is a highly regulated one, and as such, traditional marketing channels such as advertising can be limited. However, content marketing is a great way for pharmaceuticalcompanies to reach their target audience and drive sales.
Pharmaceuticalcompanies have said they will try to carve months off the time between approval and launch for new medicines in Europe, and reduce disparities between access between countries. — EFPIA (@EFPIA) April 11, 2022.
In order to incentivise innovative medicines, health technology assessment (HTA) bodies should consider evaluating the benefits that greener medicines bring to society and drive this change in the companies that are better capitalised to do so.
Given the recent rise in digital engagement and the drastic increase in digital content, it’s now essential that pharmaceuticalcompanies have a comprehensive content strategy. This enables pharma companies to simplify management of digital assets and speed up the creation, and review of new promotional materials.
To help pharmaceuticalcompanies reach patients broadly and get them engaged in meaningful actions to improve their health outcomes, this whitepaper analyses: How behavioural science can achieve lasting change.
She has an extremely wide experience of international pharmaceutical industry issues, consulting to the world’s leading pharmaceuticalcompanies on global issues. She has been vice resident, European Marketing and Thought Leadership in IQVIA for 12 years. the impact of the pandemic on medicines markets and Rx launch.
“As the contribution of costs of organic chemicals used as feedstock to the operating expenditures is small, the pharmaceuticalcompanies can spearhead and guide the transition.” Design of a Continuous Solvent Recovery System for End-to-End Integrated Continuous Manufacturing of Pharmaceuticals. 199‒208.
RSV researchers at major pharmaceuticalcompanies are currently working to develop new RSV drugs to beat future waves of RSV infection and gain the first RSV vaccine FDA approval. Pharmaceuticalcompanies are pushing to develop drugs and vaccines for RSV with these populations in mind.
QMM encompasses a range of actions including metrics, leadership commitment, culture, sustainable compliance, enhanced pharmaceutical quality systems, continual improvement, and risk management. QMM rating program is necessary to ensure patients have consistent access to the drugs they need. Next Slide ??. Michael Kopcha. Thomas Wozniewski.
Supply Chains of Quality Pharmaceuticals.” Office of Pharmaceutical Quality (OPQ) WhitePaper. By nature of their business, pharmaceuticalcompanies are more risk-centric than other sectors, such as banking. March 2023. www.fda.gov/media/165775/download 7 US Food and Drug Administration. Published 2022.
A landmark project for a major international pharmaceuticalcompany was the starting point for a series of follow-up projects in Switzerland and Germany. . Download WhitePaper. To download this whitepaper, complete the form below. Company Name. Company Type. Company Type.
To reduce the risk of cleanroom contamination, and in collaboration with a leading pharmaceuticalcompany, UV Medico has designed a breakthrough technology: The UV222 Booth. Download WhitePaper To download this whitepaper, complete the form below.
Committed to innovation, product excellence, and customer success, Veeva serves more than 975 customers, ranging from the world’s largest pharmaceuticalcompanies to emerging biotechs. Veeva is the global leader in cloud software for the life sciences industry.
Committed to innovation, product excellence, and customer success, Veeva serves more than 1,100 customers, ranging from the world’s largest pharmaceuticalcompanies to emerging biotechs. Veeva is the global leader in cloud software for the life sciences industry.
Not so China, and especially not so the lead five European countries – on average European pharmaceuticalcompanies saw a loss of 30% of the interactive time they previously had with healthcare professionals in 2020. Up to November, the US and Japan actually saw increases in interactive time in 2020. Pharma pivots East.
For example, one pharmaceuticalcompany that switched to CM reported a 50% reduction in operating costs, a 33% reduction in waste, an 80% reduction in manufacturing and testing cycle time, and a 66% reduction in time from testing to release. Journal of Pharmaceutical Sciences 104, no. WhitePaper on Continuous Bioprocessing.”
Pharmaceuticalcompanies need to be prepared to answer the call for increased demand and supply into new markets, ensuring the proper resources and logistics framework are in place.
He goes on to say that this might incentivize more pharmaceuticalcompanies to develop drugs that target the biology of aging. The incentive from the FDA’s perspective would be the possible larger effect size on multiple age-related diseases compared to that of drugs currently being developed,” he says.
Pharmaceutical sales in Brazil reached $17bn in 2021, according to GlobalData figures. Despite this, Brazil’s trade protectionist policies mean that there are few pharmaceuticalcompanies of international origin within the country. by 2040 based on statistics from OECD. </p> By Tanner Pharma Group.
However, Amgen and other pharmaceuticalcompanies have been criticised when they opted to choose the drug’s dosage based on the MTD model, which is commonly used in dose-finding trials. Impact on the industry Veal says that for a lot of pharmaceuticalcompanies there is no “big drive to think about optimizing treatment” post-licensing.
This economic change impacts employment, income, industrial production, and more, and the pharmaceutical industry will not be exempt. While larger, more established pharmaceuticalcompanies may have the infrastructure and financial cushion to fall back on, SMEs need to tread carefully through these economic challenges.
GlobalData calculates these risk scores by evaluating several qualitative and quantitative factors to establish the quality of conditions and the level of stability of the market access environment encountered by pharmaceuticalcompanies in each country.
With its highly educated, English-speaking workforce and high-quality medical facilities system, Singapore has attracted leading pharmaceuticalcompanies to open their regional headquarters in the city-state, including Novo Nordisk (Bagsvaerd, Denmark) and GSK.
This could evolve into pharmaceuticalcompanies dealing with semi-permanent higher input costs and other interlinked challenges for longer than current baseline predictions. The magnitude of the hindrance to sales growth and profitability will impact companies from multiple different angles.
Shoring these up will be a prerequisite for ushering in the age of decentralised pharmaceuticals. Pharmaceuticalcompanies need real-time visibility and insights into their supply chains to ensure patients are getting the therapies they need when they need them.
This could evolve into pharmaceuticalcompanies dealing with semi-permanent higher input costs and other interlinked challenges for longer than current baseline predictions. The magnitude of the hindrance to sales growth and profitability will impact companies from multiple different angles.
The CLR is a great option for pharmaceuticalcompanies performing steam sterilisation in the drying chamber. The CLR is temperature controlled to 160°C, enabling the highest accuracy and protection against condensation. But that isn’t the only demanding application in the freeze drying world.
Shoring these up will be a prerequisite for ushering in the age of decentralised pharmaceuticals. Pharmaceuticalcompanies need real-time visibility and insights into their supply chains to ensure patients are getting the therapies they need when they need them.
According to Baker Mackenzie , a law firm brand that specialises in a range of industries including healthcare and life sciences, IPOs allow pharmaceuticalcompanies to “access major global finance hubs and capital from a deep pool of investors around the world”.
Explaining the rise of HPAPIs, Bruno Villa, CEO, MEDELPHARM believes the trend is a consequence of the increasing pressure on pharmaceuticalcompanies to develop drugs with improved efficiency and efficacy. Within that figure, GlobalData estimates that around 60% of pipeline HPAPIs are developed to target oncology.
One antimicrobial agent that pharmaceuticalcompanies have turned to time and time again is Benzalkonium Chloride (BKC) – a well-known quaternary ammonium compound that has supported pharmaceutical formulations as far back as the 1940s. Is Benzalkonium Chloride a good choice?
Celnova Pharma is an Argentina-based pharmaceuticalcompany that centres its work around rare diseases, oncology, central nervous system, diabetes and critical care. The company currently has operations in Argentina, Colombia, Chile, Peru, and Uruguay.
These single-use technologies allow pharmaceuticalcompanies to achieve continuous manufacturing, which significantly reduces the risk of cross-contamination without the need for extensive cleaning and disinfecting.
Large-molecule drugs such as biologics are particularly sensitive to foreign contamination and E&L interaction, making these issues key concerns for pharmaceuticalcompanies. In addition, packaging components are not entirely manufactured in a clean room environment, making them a potential source of exogenous contamination.
In the 1990s, generic pharmaceuticalcompanies in the European Union (EU) offshored the manufacturing of active pharmaceutical ingredients (API) primarily to China. It was a money-saving strategy that was paying off until Covid-19 hit.
This guidance has driven many pharmaceuticalcompanies to revaluate their approach to CCIT. According to Lukas Engel, market manager pharma CCIT at Pfeiffer Vacuum, companies are increasingly looking to perform high throughput testing with sophisticated, deterministic methods.
Starting research early and using the findings to inform R&D decisions gives pharmaceuticalcompanies the best chance of success when they come to scale the many market access obstacles presented by Europe. Overall, it is never too soon to begin market access activities, but it can easily be too late.
For many years, the pharmaceutical industry has been accused of overlooking this patient population by instead targeting investments toward more prevalent indications. The stakes are high when launching an orphan drug product, however.
Most drugs used here are prescribed off-label, and experts say pharmaceuticalcompanies remain hesitant to conduct clinical trials studying gender-affirming care. Barry DeCoster, PhD, an associate professor of bioethics at the University of Michigan, describes gender affirming care as “safe and effective” for most patients.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content